Norwood, MA – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, announced topline results from the Phase 3 DETERMINE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis. Primary endpoint: The study...
Latest News
MENLO PARK, Calif. — Corcept Therapeutics Inc. (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its...
BURLINGAME, Calif. — Corvus Pharmaceuticals, Inc (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T-cell lymphoma. Soquelitinib, the Company’s lead ITK inhibitor candidate, is expected to advance into a Phase 3 registrational...
Changsha, China – New research published in Arthritis & Rheumatology suggests that for people overweight or with obesity who also have knee or hip osteoarthritis, a slow-to-moderate—but not fast—rate of weight loss caused by anti-obesity medications may lower their risk of premature death. Among 6,524 participants with knee or hip...
San Francisco, Calif. – A team of international research institutions, led by UC San Francisco, has completed the first large-scale study of posterior cortical atrophy, a baffling constellation of visuospatial symptoms that present as the first symptoms of Alzheimer’s disease. These symptoms occur in up to 10% of cases of...
Neurological diseases including Parkinson’s, Tourette’s, attention deficit hyperactivity disorder (ADHD), Alzheimer’s, and schizophrenia are all associated with alterations in dopamine-driven function involving the dopamine transporter (DAT). Research published today in the open access journal BMC Neuroscience suggests that a number of estrogens acting through their receptors affect the DAT, which...
Boston, Mass. – In the early 1990s, Mike McCune and his colleagues thought they’d found a path to a one-time HIV treatment for babies: genetically modifying hematopoietic stem cells to suppress the virus and then transplanting them into the bone marrow. But the treatment never made it to clinical trials....
A Lakewood family will bike in the 20th annual Children’s Hospital Courage Classic to help raise money for the medical center that has treated their son since birth. Stefan and Brenda Van der Steen will take part in the 3-day tour, which passes through Copper Mountain and Leadville for three...
Kuopio, Finland – A new study identifies alterations in the transcriptomic signatures in human olfactory mucosal cells of individuals with Alzheimer’s disease following SARS-CoV-2 infection, potentially contributing to exacerbated COVID-19 outcomes. The study was conducted at the University of Eastern Finland in collaboration with the University of Helsinki and published...
HOUSTON, TX — Coya Therapeutics, Inc., a clinical-stage biotechnology company developing biologics primarily focused on the restoration of regulatory T cell (Treg) immunomodulatory function, announces the presentation of data demonstrating the role of the peripheral immune system in the pathophysiology of Frontotemporal Dementia (FTD) from a biomarker study conducted at...